SG11201607334YA - Therapeutic combinations with estrogen receptor modulators - Google Patents

Therapeutic combinations with estrogen receptor modulators

Info

Publication number
SG11201607334YA
SG11201607334YA SG11201607334YA SG11201607334YA SG11201607334YA SG 11201607334Y A SG11201607334Y A SG 11201607334YA SG 11201607334Y A SG11201607334Y A SG 11201607334YA SG 11201607334Y A SG11201607334Y A SG 11201607334YA SG 11201607334Y A SG11201607334Y A SG 11201607334YA
Authority
SG
Singapore
Prior art keywords
estrogen receptor
receptor modulators
therapeutic combinations
therapeutic
combinations
Prior art date
Application number
SG11201607334YA
Other languages
English (en)
Inventor
Jeffrey H Hager
Maneval Edna Chow
Nicholas D Smith
Lori Friedman
Deepak Sampath
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201607334YA publication Critical patent/SG11201607334YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201607334YA 2014-03-13 2015-03-12 Therapeutic combinations with estrogen receptor modulators SG11201607334YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952812P 2014-03-13 2014-03-13
PCT/EP2015/055119 WO2015136016A2 (fr) 2014-03-13 2015-03-12 Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes

Publications (1)

Publication Number Publication Date
SG11201607334YA true SG11201607334YA (en) 2016-10-28

Family

ID=52706145

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607334YA SG11201607334YA (en) 2014-03-13 2015-03-12 Therapeutic combinations with estrogen receptor modulators

Country Status (14)

Country Link
US (1) US20150258080A1 (fr)
EP (1) EP3116497A2 (fr)
JP (1) JP2017507964A (fr)
KR (1) KR20160124909A (fr)
CN (1) CN106572990A (fr)
AU (1) AU2015228859A1 (fr)
CA (1) CA2940576A1 (fr)
IL (1) IL247254A0 (fr)
MA (1) MA39741A (fr)
MX (1) MX2016011636A (fr)
RU (1) RU2016137122A (fr)
SG (1) SG11201607334YA (fr)
WO (1) WO2015136016A2 (fr)
ZA (1) ZA201605712B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014281511A1 (en) 2013-06-19 2015-12-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
RU2015152171A (ru) 2013-06-19 2017-07-25 Серагон Фармасьютикалз, Инк. Азетидиновые модуляторы эстрогеновых рецепторов и их применения
JP2017509631A (ja) 2014-03-13 2017-04-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体突然変異体を調節する方法及び組成物
EP3180316A1 (fr) 2014-08-11 2017-06-21 F. Hoffmann-La Roche AG Formes cristallines de modulateur du récepteur des oestrogènes
KR102559719B1 (ko) 2014-12-18 2023-07-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
WO2016097071A1 (fr) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Modulateurs du récepteur des œstrogènes et leurs utilisations
MX2017013802A (es) 2015-04-29 2018-08-15 Radius Pharmaceuticals Inc Métodos para tratar el cáncer.
WO2016189011A1 (fr) 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Modulateurs des récepteurs d'œstrogènes hétérocycliques et leurs utilisations
TWI704137B (zh) 2015-05-29 2020-09-11 日商衛材R&D企管股份有限公司 四取代烯化合物及其等之用途
EP3359527A1 (fr) 2015-10-07 2018-08-15 H. Hoffnabb-La Roche Ag Procédé pour la préparation d'acide (e)-3-(4-((e)-2-(2-chloro-4-fluorophényl)-1-(1h-indazol-5-yl)but-1-én-1-yl)phényl)acrylique
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
RU2722441C2 (ru) * 2016-03-25 2020-06-01 Лосинь Фармасьютикал (Шанхай) Ко., Лтд. Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
EP3454856A4 (fr) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
WO2017197046A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
AU2017290748A1 (en) 2016-07-01 2019-01-17 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
CA3036568A1 (fr) * 2016-09-27 2018-04-05 Radius Health, Inc. Methodes de traitement du cancer de l'ovaire
SG10201913951YA (en) 2016-10-11 2020-03-30 Univ Duke Lasofoxifene treatment of er+ breast cancer
CN107973780B (zh) * 2016-10-21 2020-10-09 四川科伦博泰生物医药股份有限公司 一种取代的烯烃类化合物及其制备方法和用途
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
US20190337921A1 (en) * 2016-11-24 2019-11-07 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use
JP6346368B1 (ja) 2016-11-28 2018-06-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 インダゾール誘導体の塩及びその結晶
HRP20231537T1 (hr) * 2016-12-01 2024-03-15 Arvinas Operations, Inc. Derivati tetrahidronaftalena i tetrahidroizokinolina kao degradatori estrogenskih receptora
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
AU2018234903B2 (en) 2017-03-16 2024-02-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
NZ759691A (en) 2017-06-29 2023-05-26 G1 Therapeutics Inc Morphic forms of git38 and methods of manufacture thereof
CN111032627B (zh) * 2017-09-25 2023-10-20 罗欣健康科技发展(北京)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
JP2021503448A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー Ｌｓｚ１０２及びリボシクリブを含む医薬組合せ
JP2021504384A (ja) 2017-12-01 2021-02-15 ノバルティス アーゲー Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ
EP3773524A4 (fr) 2018-04-10 2021-12-22 Duke University Traitement du cancer du sein avec du lasofoxifène
PE20211207A1 (es) 2018-06-21 2021-07-05 Hoffmann La Roche Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1- (3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso
WO2020132561A1 (fr) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Dégradation ciblée de protéines
CA3144791A1 (fr) * 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimes d'antagonistes du recepteur des oestrogenes
WO2022026900A2 (fr) * 2020-07-30 2022-02-03 Acer Therapeutics Inc. Antagonistes du récepteur nk pour patients atteints d'un cancer
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2024030968A1 (fr) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Composés pour moduler la protéine ret
WO2024033513A1 (fr) 2022-08-11 2024-02-15 Diaccurate Composés pour le traitement du cancer
WO2024097989A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Agents de dégradation de protéine ret-ldd
WO2024097980A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Inhibiteurs de protéines ret-ldd

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2007246793B2 (en) 2006-04-26 2013-02-07 F. Hoffmann-La Roche Ag Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2011031861A1 (fr) * 2009-09-09 2011-03-17 Quintiles Transnational Corp. Procédés pour la prédiction de la sensibilité d’une maladie ou d’un trouble à un inhibiteur de la tyrosine kinase de récepteurs par l’analyse de mutations dans le gène pik3ca
CN104744491B (zh) 2009-09-28 2017-07-11 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法
EP3205648A1 (fr) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Modulateur du récepteur oestrogénique et utilisation de ces derniers
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EA029559B1 (ru) * 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
CA2857061A1 (fr) * 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Nouveaux composes benzopyranes, compositions et utilisations de ceux-ci
WO2013116293A1 (fr) * 2012-01-31 2013-08-08 Novartis Ag Combinaison d'un inhibiteur de rtk avec un anti-œstrogène et son utilisation pour traiter le cancer
CN104220426B (zh) 2012-03-20 2017-03-01 塞拉根制药公司 雌激素受体调节剂及其用途
EP3545968A1 (fr) * 2012-06-08 2019-10-02 F. Hoffmann-La Roche AG Sélectivité mutante et combinaisons d'un composé inhibiteur de phosphoinositide kinase 3 et d'agents chimiothérapeutiques pour le traitement du cancer
KR101435193B1 (ko) 2012-08-10 2014-09-01 주식회사 일광 자동차용 사이드 임팩트바 제조 방법
BR112015022566A2 (pt) 2013-03-14 2017-07-18 Seragon Pharmaceuticals Inc composto e composição farmacêutica
WO2014203132A1 (fr) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Composés de benzopyran substitués, leurs compositions et utilisations
AU2014281511A1 (en) * 2013-06-19 2015-12-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
RU2015152171A (ru) 2013-06-19 2017-07-25 Серагон Фармасьютикалз, Инк. Азетидиновые модуляторы эстрогеновых рецепторов и их применения
WO2014203129A1 (fr) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinaisons de composés benzopyrane, leurs compositions et utilisations

Also Published As

Publication number Publication date
IL247254A0 (en) 2016-09-29
RU2016137122A (ru) 2018-04-18
WO2015136016A2 (fr) 2015-09-17
WO2015136016A3 (fr) 2015-12-10
MX2016011636A (es) 2016-12-12
AU2015228859A1 (en) 2016-07-07
JP2017507964A (ja) 2017-03-23
ZA201605712B (en) 2019-04-24
EP3116497A2 (fr) 2017-01-18
KR20160124909A (ko) 2016-10-28
CN106572990A (zh) 2017-04-19
US20150258080A1 (en) 2015-09-17
MA39741A (fr) 2017-01-18
RU2016137122A3 (fr) 2018-10-19
CA2940576A1 (fr) 2015-09-17

Similar Documents

Publication Publication Date Title
ZA201605712B (en) Therapeutic combinations with estrogen receptor modulators
HK1247199A1 (zh) 雌激素受體調節劑及其用途
IL285318A (en) Estrogen receptor modulators
HK1253558A1 (zh) 法尼醇x受體調節劑
GB201514875D0 (en) Receptor
HK1252163A1 (zh) 受體
PL3132034T3 (pl) Środek terapeutyczny
HK1255160A1 (zh) 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途
IL274537A (en) nuclear receptor modulators
ZA201700342B (en) Novel glp-1 receptor modulators
EP3224261A4 (fr) Modulateurs du récepteur opioïde
GB201410216D0 (en) Therapeutic
IL249203A0 (en) Androgen receptor modulators and methods of using them
GB201510637D0 (en) Therapeutic
IL252565A0 (en) New receptor modulators
EP3224230A4 (fr) Modulateurs du récepteur des strogènes
HK1243457A1 (zh) 通道調節劑
GB201405403D0 (en) Receptor modulation
GB201504285D0 (en) Receptor modulation
GB201400215D0 (en) Modulators
GB201418508D0 (en) Therapeutic
GB201413719D0 (en) Therapeutic
GB201410832D0 (en) Therapeutic
GB201410334D0 (en) Therapeutic
GB201406674D0 (en) Therapeutic